文献速递中枢神经肿瘤放疗放疗物理与技术

肿瘤电场阵列不降低胶质母细胞瘤放疗靶区覆盖率

Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy.
PubMed 文献 · Adv Radiat Oncol · 2019-08-28

该研究将10例胶质母细胞瘤患者的放疗计划复制到颅骨模体并重新优化,在模体头皮不同位置放置肿瘤电场阵列后重新计算剂量分布,比较靶区覆盖与皮肤剂量。结果显示阵列存在时单一位点PTV V97%和D97%最大分别下降1.7%和2.7%,但重新定位可减轻该下降;3个位点平均后所有PTV覆盖参数与无阵列相比无统计学显著差异。

要点

  • 肿瘤电场阵列单一位点放置可使PTV V97%和D97%最大分别下降1.7%和2.7%。
  • 阵列重新定位可减轻剂量学变化,3个位点平均后PTV覆盖参数无显著差异。
  • 队列皮肤D1cc和D20cc平均增加3.1%,但被认为无临床显著性。

核心结论

  • 肿瘤电场阵列放置不显著影响靶区体积覆盖,重新定位可进一步最小化剂量学变化并消除阵列移动时重新计划的需要。

研究设计与样本

  • 将10例连续胶质母细胞瘤患者的放疗计划复制到颅骨模体并针对模体解剖重新优化,在3次额外CT扫描中于模体头皮不同位置放置肿瘤电场电极阵列后重新计算剂量分布。

主要发现

  • 单一位点阵列存在时PTV V97%和D97%最大分别下降1.7%和2.7%,重新定位可减轻该下降。
  • 3个阵列位置平均后,所有病例的PTV覆盖剂量学参数(V95-97%、D95-97%)与无阵列相比无统计学显著差异。
  • 队列皮肤D1cc和D20cc平均增加3.1%。
  • 肿瘤电场电极的表面剂量低于5-mm superflab bolus。

关键数值与推荐

  • PTV覆盖参数包括V95-97%和D95-97%,单一位点阵列使PTV V97%和D97%最大分别下降1.7%和2.7%。
  • 3个阵列位置平均后PTV覆盖参数与无阵列相比无统计学显著差异。
  • 皮肤D1cc和D20cc平均增加3.1%。
  • 肿瘤电场电极表面剂量低于5-mm superflab bolus。

临床怎么用

  • 临床使用中按需重新定位肿瘤电场阵列可最小化剂量学变化,阵列移动时无需重新计划。
  • 阵列带来的轻微bolus效应使皮肤剂量略有增加,但计算增幅无临床显著性。

局限性

  • 研究基于颅骨模体而非患者体内剂量测量,样本量为10例患者计划。
  • 原文未报告临床结局、毒性或治疗疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To inform development of procedures for using tumor-treating field arrays (TTFields) during glioblastoma radiation therapy by determining whether the placement and repositioning of arrays affects target volume coverage and cranial skin dose. METHODS AND MATERIALS: Radiation plans from 10 consecutive patients treated for glioblastoma were copied to a cranial phantom and reoptimized for phantom anatomy. Dose distributions were then recalculated on 3 additional computed tomographic scans of the phantom with the TTFields electrode arrays placed over distinct locations on the phantom scalp to compare planning target volume (PTV) coverage and skin dose with and without TTFields in place in varying positions. Percent depth dose curves were also measured for radiation beams passing through the electrodes and compared with commonly used bolus material. RESULTS: The presence of TTFields arrays decreased PTV V97% and D97% by as much as 1.7% and 2.7%, respectively, for a single array position, but this decrease was mitigated by array repositioning. On averaging the 3 array positions, there was no statistically significant difference in any dosimetric parameter of PTV coverage (V95-97%, D95-97%) across all cases compared with no array. Mean increases in skin D1cc and D20cc of 3.1% were calculated for the cohort. Surface dose for TTFields electrodes was less than that with a 5-mm superflab bolus. CONCLUSIONS: Our work demonstrates that placement of TTFields arrays does not significantly affect target volume coverage. We show that repositioning of TTFields arrays, as is required in clinical use, further minimizes any dosimetric changes and eliminates the need for replanning when arrays are moved. A slight, expected bolus effect is observed, but the calculated increases in skin dose are not clinically significant. These data support the development of clinical trials to assess the safety and efficacy of combining concurrent chemoradiotherapy with TTFields therapy for glioblastoma.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Stachelek GC, Grimm J, Moore J, et al. Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy. Adv Radiat Oncol. 2019. PMID: 32051891. doi:10.1016/j.adro.2019.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。